# Novo Nordisk: EU Authorities Recommend Weight Loss Treatment ### Key Points: – The European Medicines Agency (EMA) has recommended semaglutide for the treatment of obesity. – Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved for type 2 diabetes. – The European Commission is expected to make a decision within two months following the EMA recommendation. – If approved, semaglutide would be the first injectable treatment for chronic weight management in non-diabetic individuals. Novo Nordisk, a leading pharmaceutical company, has made significant strides in the treatment of obesity with the recommendation from the EMA for semaglutide. This development highlights the potential for semaglutide to address the unmet need for effective weight loss treatments. ### Hot Take: The recommendation of semaglutide by EU authorities is a positive step towards providing individuals with a new option for managing obesity. Contact Mindful Evolution today to learn more about weight management options through telehealth services available in AL, AR, FL, GA, LA, MS, NC, NY, SC, TN, TX, and VA. Weight loss disclaimer: Individual results may vary. — Please contact us for your weight management solutions at Mindful Evolution: https://yourmindfulevolution.com or call or text us at 954-639-9960.